Study of KC1036 with immunotherapy and chemo for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called KC1036 combined with standard immunotherapy and chemotherapy for people with advanced esophageal cancer that has not been treated before. The goal is to see if this combination can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have squamous cell carcinoma of the esophagus or the junction between the esophagus and stomach that has spread or come back.
- You have not had any previous treatment for this advanced stage of cancer.
- You have at least one tumor that can be measured on scans.
- You are in good enough health to be up and about (able to care for yourself).
- You do not have serious medical conditions like active infections, other cancers in the last 5 years, or uncontrolled fluid buildup.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a new combination of immunotherapy (toripalimab) with two chemotherapy drugs before surgery for esophageal cancer, compared to a standard chemo regimen. The goal is to see if the new combination improves outcomes for patients with resectable tumors.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, and low-dose radiation for people with esophageal cancer that did not shrink after initial chemotherapy and immunotherapy. The goal is to see if this new combination can help control the cancer before surgery.
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.